Thomas Pietschmann



  1. Vieyres G, Pietschmann T. HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells. 2019;8: pubmed publisher
  2. Pietschmann T, Brown R. Hepatitis C Virus. Trends Microbiol. 2019;27:379-380 pubmed publisher
    ..Approximately 71 million people are chronically infected and 1.7 million new infections occur annually. Treatment-induced cure does not protect from viral reinfection. A prophylactic vaccine is under development. ..
  3. Banda D, Perin P, Brown R, Todt D, Solodenko W, Hoffmeyer P, et al. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. J Hepatol. 2019;: pubmed publisher
    ..It defines viral properties that determine sensitivity to these molecules and thus provides information to identify patients that may benefit from treatment with membrane fusion inhibitors. ..
  4. Khera T, Behrendt P, Bankwitz D, Brown R, Todt D, Doepke M, et al. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. J Hepatol. 2019;70:593-602 pubmed publisher
  5. Banse P, Moeller R, Bruening J, Lasswitz L, Kahl S, Khan A, et al. CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. Viruses. 2018;10: pubmed publisher
    ..We demonstrate that a cholesterol-coordinating glutamate residue in CD81, which hCD9 lacks, promotes HCV infection. This work highlights the hCD81 non-LEL regions as additional HCV susceptibility-determining factors. ..
  6. Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, et al. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. J Virol. 2014;88:12644-55 pubmed publisher
    ..Furthermore, these findings highlight separable functions of SR-BI during HCV cell entry and reveal a novel role of HVR1 for the properties of virus-associated lipoproteins. ..
  7. Tarr A, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, et al. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses. 2015;7:3995-4046 pubmed publisher
    ..Here we review current knowledge of HCV envelope protein structure, integrating knowledge of genetic, antigenic and functional diversity to inform rational immunogen design. ..
  8. Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. J Virol. 2015;90:3065-73 pubmed publisher
    ..Therefore, this system will be highly useful to study hRSV cell entry and host factor usage and to explore antiviral strategies targeting hRSV cell entry. ..
  9. Anggakusuma -, Brown R, Banda D, Todt D, Vieyres G, Steinmann E, et al. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. J Virol. 2016;90:10670-10681 pubmed publisher
    ..Therefore, cleavage of MAVS is a common strategy of hepaciviruses, and human MAVS is likely unable to limit replication of these nonhuman viruses upon zoonotic exposure. ..

More Information


  1. Pietschmann T. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. J Virol. 2017;91: pubmed publisher
    ..Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections. ..
  2. Anggakusuma -, Frentzen A, Gürlevik E, Yuan Q, Steinmann E, Ott M, et al. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons. J Virol. 2015;89:3833-45 pubmed publisher
    ..Characterization of type I or type III-dependent interferon-stimulated genes in these cells should help to identify key murine restriction factors that preclude HCV propagation in immunocompetent mouse liver cells. ..
  3. Gerold G, Meissner F, Bruening J, Welsch K, Perin P, Baumert T, et al. Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Rep. 2015;12:864-78 pubmed publisher
    ..These results demonstrate the use of quantitative proteomics to elucidate pathogen entry and underscore the importance of host protein-protein interactions during HCV invasion. ..
  4. Gerold G, Bruening J, Pietschmann T. Decoding protein networks during virus entry by quantitative proteomics. Virus Res. 2016;218:25-39 pubmed publisher
  5. Bankwitz D, Doepke M, Hueging K, Weller R, Bruening J, Behrendt P, et al. Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. J Hepatol. 2017;67:480-489 pubmed publisher
    ..Lay summary: This study shows that HCV particle infectivity is remodeled by secreted ApoE after particle release from cells. Fluctuation of the availability of ApoE likely influences HCV infectivity, antibody escape and transmission. ..
  6. Weller R, Hueging K, Brown R, Todt D, Joecks S, Vondran F, et al. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. J Virol. 2017;91: pubmed publisher
    ..Thus, strain-dependent features of HCV modulate ApoE usage, with implications for virus fitness at the level of assembly and cell entry. ..
  7. Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves M, et al. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Res. 2017;147:19-28 pubmed publisher
    ..The low cost and wide availability of this compound make it a promising candidate for HCV combination therapies, and also emerging human pathogenic flaviviruses like ZIKV. ..